Literature DB >> 9096448

Helicobacter pylori and uremic gastritis: a histopathologic study and a correlation with endoscopic and bacteriologic findings.

F E Moustafa1, A Khalil, M Abdel Wahab, M A Sobh.   

Abstract

In this work 70 asymptomatic uremic patients under maintenance hemodialysis in our institution underwent upper-gastrointestinal endoscopy as part of a routine investigation prior to kidney transplantation. Their endoscopic findings were scored and antral mucosal biopsies were obtained and subjected to histopathologic and bacteriologic assessment. Bacteriologic examination included culture, rapid urease test, and microscopic examination for detection of Helicobacter pylori. Histopathologic examination of the gastric mucosa showed chronic superficial gastritis in 52%, atrophic gastritis in 5.7% and intestinal metaplasia in 37% of the cases. Of the cases with superficial gastritis, 5 showed in addition gastric mucosal dysplastic changes. There was no correlation between the histopathologic and endoscopic findings. Nevertheless, there was a significant association between histopathologic changes and H. pylori infection (p = 0.0001). All cases with atrophic gastritis showed H. pylori, and of 24 cases with chronic active superficial gastritis. H. pylori was detected in 18, while it was detected in only 2 of 13 cases with chronic inactive superficial gastritis and in 4 of 29 cases with normal antral mucosal biopsies. Among different variables in dialysis patients, only patients' ages were found to have significant association with H. pylori infection (p < 0.03). We have concluded that in asymptomatic uremic patients under maintenance hemodialysis, relying only on endoscopy for critical assessment of the upper gastrointestinal tract is unsatisfactory and histopathologic examination of the antral mucosal biopsies is mandatory. Chronic superficial gastritis and atrophic gastritis should be expected in up to 60% of the patients, and there is a strong association between H. pylori infection and gastritis.

Entities:  

Mesh:

Year:  1997        PMID: 9096448     DOI: 10.1159/000169092

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  6 in total

Review 1.  Review of Helicobacter pylori infection and chronic renal failure.

Authors:  Mitsushige Sugimoto; Yoshio Yamaoka
Journal:  Ther Apher Dial       Date:  2010-08-31       Impact factor: 1.762

2.  Helicobacter pylori eradication with a 7-day low-dose triple therapy in hemodialysis patients.

Authors:  Won-Chul Chang; Young-Il Jo; Hyung-Seok Park; Joon Jegal; Jung-Hwan Park; Jong-Ho Lee; Choon-Jo Jin
Journal:  Clin Exp Nephrol       Date:  2010-07-15       Impact factor: 2.801

3.  Helicobacter pylori status and esophagogastroduodenal mucosal lesions in patients with end-stage renal failure on maintenance hemodialysis.

Authors:  Tomohiko Moriyama; Takayuki Matsumoto; Katsuya Hirakawa; Hirofumi Ikeda; Kazuhiko Tsuruya; Hideki Hirakata; Mitsuo Iida
Journal:  J Gastroenterol       Date:  2010-01-19       Impact factor: 7.527

4.  Helicobacter pylori infection and gastroduodenal lesions in children with chronic kidney disease stage V.

Authors:  Oguz Canan; Figen Ozcay; Ferda Ozbay-Hosnut; Nurcan Cengiz; Esra Baskın
Journal:  Pediatr Nephrol       Date:  2012-07-29       Impact factor: 3.714

5.  Prevalence of Helicobacter pylori infection in long-term hemodialysis patients.

Authors:  Mitsushige Sugimoto; Kyoko Sakai; Masakazu Kita; Jiro Imanishi; Yoshio Yamaoka
Journal:  Kidney Int       Date:  2008-10-08       Impact factor: 10.612

6.  Uremia-Induced Gut Barrier Defect in 5/6 Nephrectomized Mice Is Worsened by Candida Administration through a Synergy of Uremic Toxin, Lipopolysaccharide, and (1➔3)-β-D-Glucan, but Is Attenuated by Lacticaseibacillus rhamnosus L34.

Authors:  Somkanya Tungsanga; Wimonrat Panpetch; Thansita Bhunyakarnjanarat; Kanyarat Udompornpitak; Pisut Katavetin; Wiwat Chancharoenthana; Piraya Chatthanathon; Naraporn Somboonna; Kriang Tungsanga; Somying Tumwasorn; Asada Leelahavanichkul
Journal:  Int J Mol Sci       Date:  2022-02-24       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.